3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
12
SHPH Quote, Financials, Valuation and Earnings
Last price:
$0.39
Seasonality move
:
-19.44%
Day range:
$0.35 - $0.41
52-week range:
$0.33 - $4.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.70x
Volume:
51.1K
Avg. volume:
201K
1-year change:
-88.02%
Market cap:
$1.9M
Revenue:
--
EPS (TTM):
-$3.77
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Shuttle Pharmaceuticals Holdings has -- downside to fair value with a price target of -- per share.
SHPH vs. S&P 500
-
Over the past 5 trading days, Shuttle Pharmaceuticals Holdings has overperformed the S&P 500 by 0.34% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Shuttle Pharmaceuticals Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Shuttle Pharmaceuticals Holdings has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Shuttle Pharmaceuticals Holdings reported revenues of --.
Earnings Growth
-
Shuttle Pharmaceuticals Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Shuttle Pharmaceuticals Holdings reported earnings per share of -$0.39.
Enterprise value:
867K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$2.3M | -$5.9M | -$7.7M | -$1.3M | -$1.8M | |
| EBITDA | -$4.5M | -$4M | -$7.8M | -$1M | -$1.4M | |
| Diluted EPS | -$4.80 | -$3.52 | -$3.77 | -$0.81 | -$0.39 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $509.6K | $8.6M | $5.6M | $2.2M | |
| Total Assets | -- | $651.6K | $8.7M | $6M | $2.5M | |
| Current Liabilities | -- | $2.2M | $975.7K | $1M | $1.5M | |
| Total Liabilities | -- | $2.3M | $975.7K | $1.9M | $1.8M | |
| Total Equity | -- | -$1.6M | $7.7M | $4.1M | $709.2K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.7M | -$5.6M | -$7.3M | -$1.1M | -$2.7M | |
| Cash From Investing | -- | -$2.8M | $2.9M | $87K | -- | |
| Cash From Financing | $10.6M | $2.6M | $3.8M | -$334.4K | $4.5M | |
| Free Cash Flow | -$2.7M | -$5.6M | -$7.3M | -$1.1M | -$2.7M | |
SHPH
Sector
Market Cap
$1.9M
$37M
Price % of 52-Week High
8.26%
43.14%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
-88.02%
-43.58%
Beta (5-Year)
--
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.40
200-day SMA
Sell
Level
$1.54
Bollinger Bands (100)
Sell
Level
0.5 - 1.04
Chaikin Money Flow
Sell
Level
-30.3M
20-day SMA
Sell
Level
$0.44
Relative Strength Index (RSI14)
Sell
Level
34.28
ADX Line
Sell
Level
16.42
Williams %R
Neutral
Level
-67.5978
50-day SMA
Sell
Level
$0.62
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
78.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Stock Forecast FAQ
In the current month, SHPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SHPH average analyst price target in the past 3 months is --.
-
Where Will Shuttle Pharmaceuticals Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Shuttle Pharmaceuticals Holdings share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Shuttle Pharmaceuticals Holdings?
Analysts are divided on their view about Shuttle Pharmaceuticals Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Shuttle Pharmaceuticals Holdings is a Sell and believe this share price will rise from its current level to --.
-
What Is Shuttle Pharmaceuticals Holdings's Price Target?
The price target for Shuttle Pharmaceuticals Holdings over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SHPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Shuttle Pharmaceuticals Holdings is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SHPH?
You can purchase shares of Shuttle Pharmaceuticals Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Shuttle Pharmaceuticals Holdings shares.
-
What Is The Shuttle Pharmaceuticals Holdings Share Price Today?
Shuttle Pharmaceuticals Holdings was last trading at $0.39 per share. This represents the most recent stock quote for Shuttle Pharmaceuticals Holdings. Yesterday, Shuttle Pharmaceuticals Holdings closed at $0.39 per share.
-
How To Buy Shuttle Pharmaceuticals Holdings Stock Online?
In order to purchase Shuttle Pharmaceuticals Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 18.54% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 13.06% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 3.25% over the past day.
